The study was conducted using a mice model where the mice was given one-dose and two-dose regimens of the vaccine.
The findings revealed that mice immunized twice with the vaccine had developed protective antibodies against the deadly virus
The mice injected with the vaccine through the muscle developed more antibodies in the blood, while mice that received through nasal had more antibodies in their lungs.
Dr. Ross said that VLPs easy to develop produce, manufacture and could be generated within ten weeks.
The study appears in Jan. 30 issue of PLoS ONE.
Source-ANI
SRM/L